Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
View/ Open
ICR Author
Author
Tiong, IS
Dillon, R
Ivey, A
Teh, T-C
Nguyen, P
Cummings, N
Taussig, DC
Latif, A-L
Potter, NE
Runglall, M
Russell, NH
Raj, K
Schwarer, AP
Fong, CY
Grigg, AP
Wei, AH
Type
Journal Article
Metadata
Show full item recordAbstract
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1<sup>mut</sup> measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR<sub>MRD-</sub> ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR<sub>MRD-</sub> after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1<sup>mut</sup> MRD.
Collections
Subject
Humans
Neoplasm, Residual
Sulfonamides
Neoplasm Proteins
Nuclear Proteins
Retrospective Studies
Mutation
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Male
Leukemia, Myeloid, Acute
Bridged Bicyclo Compounds, Heterocyclic
Nucleophosmin
Research team
Acute Leukaemia
Language
eng
Date accepted
2020-04-14
Citation
British journal of haematology, 2021, 192 (6), pp. 1026 - 1030